Neuroendocrine carcinomas of the lung: a critical analysis.
Neuroendocrine carcinomas represent an important group of primary neoplasms in the lung. During the last decades, the nomenclature of these tumors has evolved and the current use of immunohistochemical and molecular biology studies have, to some extent, expanded the conventional view of these tumors. However, the primary diagnosis of most of these lesions is performed on limited biopsy specimens, which may not translate well when one is confronted with a nomenclature that is based on resected material. In addition, for some of these specific entities, some confusion and controversy apparently remain, allowing for the proliferations of different terms that, although they may be dismissed as "semantics," may have a role in interpretation, further subclassification, and, possibly, treatment. Herein we review current concepts regarding the classification of these neoplasms and the role of this classification in our daily practice and discuss how it may impact treatment.
Moran
Cesar A
CA
Department of Pathology, University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Suster
Saul
S
Coppola
Domenico
D
Wick
Mark R
MR
D014408:Biomarkers, Tumor / Q000032:analysis; D018278:Carcinoma, Neuroendocrine / Q000737:chemistry / Q000473:pathology*; D003951:Diagnostic Errors / Q000517:prevention & control; D006801:Humans; D008175:Lung Neoplasms / Q000737:chemistry / Q000473:pathology*; D009626:Terminology as Topic
D014408:Biomarkers, Tumor